🇨🇭#RO #отчетность
Roche
Q1 Group sales = +11% to CHF16.45B
Pharmaceuticals Division sales = +6% to CHF11.2B
Ronapreve (REGEN-COV) sales = +272% to CHF 587M.
Roche
Q1 Group sales = +11% to CHF16.45B
Pharmaceuticals Division sales = +6% to CHF11.2B
Ronapreve (REGEN-COV) sales = +272% to CHF 587M.
⚡️🇪🇺#RO #отчетность
Roche H1 22 Earnings
- H1 Core EPS CHF 11.76 (est CHF 11.05)
- H1 Revenue CHF 32.03B (est CHF 31.89B)
- Confirms FY 22 Outlook
Roche H1 22 Earnings
- H1 Core EPS CHF 11.76 (est CHF 11.05)
- H1 Revenue CHF 32.03B (est CHF 31.89B)
- Confirms FY 22 Outlook